StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued on Saturday. The brokerage set a “hold” rating on the stock.

A number of other brokerages have also recently commented on EKSO. Lake Street Capital lowered their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright cut their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.

Ekso Bionics Price Performance

Shares of EKSO stock opened at $0.58 on Friday. The firm’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $1.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. Ekso Bionics has a 52-week low of $0.50 and a 52-week high of $3.13. The stock has a market cap of $12.76 million, a PE ratio of -0.89 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter in the prior year, the business earned ($0.24) earnings per share. As a group, analysts forecast that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.